# Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation

> **NCT00401219** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Estrogen Replacement Therapy

## Interventions

- **DRUG:** conjugated estrogens/progestin (MPA)

## Key facts

- **NCT ID:** NCT00401219
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2007-02
- **Target enrollment:** — (—)
- **Last updated:** 2007-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401219, "Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00401219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*